Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Kimia Farma Persero TbkISX:KAEF -0.92%57 EBITDA Margin % is 6.25% as of Jun. 2026, which is 21% below its 10-year median of 7.96. GuruFocus rates ISX:KAEF with a GF Score™ of 57/100 and a GF Value™ of Rp579.40 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 119 Medical Distribution companies, PT Kimia Farma Persero Tbk ranks better than 63.87% on this metric.
PT Kimia Farma Persero Tbk (ISX:KAEF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PT Kimia Farma Persero Tbk EBITDA Margin % Related Terms
PT Kimia Farma Persero Tbk EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:KAEF vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, PT Kimia Farma Persero Tbk's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kimia Farma Persero Tbk EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Persero Tbk's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PT Kimia Farma Persero Tbk's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kimia Farma Persero Tbk (ISX:KAEF) has a EBITDA Margin % of 6.25% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Kimia Farma Persero Tbk and its competitors. This is 21% below median its historical median of 7.96. According to the industry distribution chart, PT Kimia Farma Persero Tbk ranks #43 out of 119 companies in the Medical Distribution industry, placing it in the top 36.1%.
Is PT Kimia Farma Persero Tbk's EBITDA Margin % too high?
PT Kimia Farma Persero Tbk's current EBITDA Margin % of 6.25% is 21% below median its 10-year median of 7.96. The Medical Distribution industry median EBITDA Margin % is 4.27. PT Kimia Farma Persero Tbk's value of 6.25% is 46.4% above this industry median. Based on the distribution chart, PT Kimia Farma Persero Tbk ranks #43 out of 119 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, PT Kimia Farma Persero Tbk has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Persero Tbk's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Persero Tbk ranks #43 out of 119 companies for EBITDA Margin %. This puts PT Kimia Farma Persero Tbk in the upper half of its industry. The industry median EBITDA Margin % is 4.27. PT Kimia Farma Persero Tbk's value of 6.25% is 46.4% above this benchmark. While the company's 10-year median is 7.96 vs. the industry median of 4.27, PT Kimia Farma Persero Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.27, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kimia Farma Persero Tbk's current EBITDA Margin % of 6.25% is 46.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Kimia Farma Persero Tbk and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Persero Tbk's current EBITDA Margin % is 6.25%, which is 21% below median its own 10-year median of 7.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Persero Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp579.40, compared to a current price of Rp432.00 — trading 25.4% below its estimated fair value. The current EBITDA Margin % is 6.25%, which is 21% below median its 10-year median of 7.96 and 46.4% above the Medical Distribution industry median of 4.27. PT Kimia Farma Persero Tbk's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PT Kimia Farma Persero Tbk (ISX:KAEF), the current EBITDA Margin % is 6.25% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Persero Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk stock appears to be undervalued.
The current stock price of Rp432.00 is trading 25.4% below its estimated GF Value™ of Rp579.40.
GuruFocus considers PT Kimia Farma Persero Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
EBITDA Margin %: 6.25% (21% below median its 10-year median of 7.96)
GF Value™: Rp579.40 vs. price of Rp432.00 (25.4% below fair value)
Industry Position: 46.4% above the Medical Distribution median (#43 of 119)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
57GF Score
Get the complete analysis for ISX:KAEF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
